Fixed: 15   unfixed:10
-------------------------------------------------------------------------------

***single-chain antibodies: fixed by adding a complementary chain ***
[Heavy chain only] 6 
sequence in:
DATA/paperData/dataForClusterResidues/tmp/abWithPdbErr/tmp/abnum/singleChainSeqPaired/

pdb paired in:
DATA/paperData/dataForClusterResidues/tmp/abWithPdbErr/tmp/pdb/pdbPaired/H/

pdb corrected in:
DATA/paperData/dataForClusterResidues/tmp/abWithPdbErr/tmp/pdb/pdbCorrectedForSingleChain/

caplacizumab
lexatumumab
otlertuzumab
ozoralizumab
palivizumab
vobarilizumab
-------------------------------------------------------------------------------
[Light chain only] 4 
sequence in:
DATA/paperData/dataForClusterResidues/tmp/abWithPdbErr/tmp/abnum/singleChainSeqPaired/

pdb paired in:
DATA/paperData/dataForClusterResidues/tmp/abWithPdbErr/tmp/pdb/pdbPaired/L/

pdb corrected in:
DATA/paperData/dataForClusterResidues/tmp/abWithPdbErr/tmp/pdb/pdbCorrectedForSingleChain/

emicizumab
lulizumab_pegol
naptumomab_estafenatox
placulumab
-------------------------------------------------------------------------------
***fixed by convert the DOS file *** 3
sequence fixed in:
DATA/paperData/dataForClusterResidues/tmp/abWithPdbErr/tmp/abnum/DOSSeqCorrected/

pdb corrected in:
DATA/paperData/dataForClusterResidues/tmp/abWithPdbErr/tmp/pdb/pdbCorrectedForDOSError/

bapineuzumab
nimotuzumab
ocrelizumab
-------------------------------------------------------------------------------
*** fixed by excluding CA-only model *** 2
sequence in:
DATA/paperData/dataForClusterResidues/tmp/abWithPdbErr/tmp/abnum/withCAOnlyModel/

pdb corrected in:
DATA/paperData/dataForClusterResidues/tmp/abWithPdbErr/tmp/pdb/pdbCorrectedExludingCAOnlyModel/

bimekizumab	H: 4c2i0
88BV59          H: 4c2i0 
-------------------------------------------------------------------------------
***unable to fix *** 10
sequence in:
DATA/paperData/dataForClusterResidues/tmp/abWithPdbErr/tmp/abnum/unfixedSeq/

blontuvetmab   /
clazakizumab   /
dupilumab      /
mavrilimumab   /
rafivirumab    /
rovalpituzumab /
tenatumomab    /
teprotumumab   /
tovetumab      /
CDP571         /



